Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Esophageal Squamous Cell Carcinoma 5Esophageal Neoplasms 3Advanced Solid Tumor 3Stomach Neoplasms 2Lung Neoplasms 2Cholangiocarcinoma 2Advanced Lung Cancer 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous NSCLC 1Solid Tumor 1SCLC 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Non-Squamous Non-Small Cell Lung Cancer 1Neoplasms, Unknown Primary 1Neoplasms, Squamous Cell 1Neoplasms 1Neoplasm Metastasis 1Locally Advanced Rectal Cancer 1Liver Neoplasms 1Liver Diseases 1High-Risk Resectable NSCLC 1Gastrointestinal Diseases 1Esophageal Diseases 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

sintilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced/Metastatic Solid Malignancies × sintilimab × Clear all
NCT03568539 2021-06-01

IBI308 in Subjects With Advanced/Metastatic Solid Malignancies

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
39 enrolled 16 charts

Advanced/Metastatic Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡